Ureteral Stent-related Pain and Mirabegron (SPAM) Trial
Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Ureteric stents are used often following ureteroscopy for prevention of obstruction from
edema and or stone fragments. They are often associated with pain, voiding often, the need to
urinate quickly and finding blood in the urine called "lower urinary tract symptoms" or LUTS
for short. There is randomized studies showing the efficacy of α-blockers such as tamsulosin
in relieving "stent symptoms" (pain and LUTS). There is emerging but limited evidence to show
that antimuscarinic medications, used to treat overactive bladder (OAB) have some efficacy in
decreasing stent symptoms. Mirabegron is a beta-agonist used to decrease OAB symptoms.
Mirabegron functions to mediate relaxation of the detrusor muscle and has been useful in
treating OAB symptoms. Conventional antimuscarinic medications often have bothersome side
effects like dry mouth, constipation, blurred vision and cognitive impairment. This may limit
their use in some populations. Mirabegron is well-tolerated with a good safety profile and
therefore may be useful in treating stent symptoms without the bothersome side effects
commonly seen with antimuscarinic medications. .
The investigators hypothesize that mirabegron is effective in decreasing ureteral stent
related LUTS and pain.